These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 24589263)

  • 21. An Investigation of Structure-Activity Relationships of Azolylacryloyl Derivatives Yielded Potent and Long-Acting Hemoglobin Modulators for Reversing Erythrocyte Sickling.
    Omar AM; Abdulmalik O; Ghatge MS; Muhammad YA; Paredes SD; El-Araby ME; Safo MK
    Biomolecules; 2020 Nov; 10(11):. PubMed ID: 33147875
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design, Synthesis, and Investigation of Novel Nitric Oxide (NO)-Releasing Aromatic Aldehydes as Drug Candidates for the Treatment of Sickle Cell Disease.
    Huang B; Ghatge MS; Donkor AK; Musayev FN; Deshpande TM; Al-Awadh M; Alhashimi RT; Zhu H; Omar AM; Telen MJ; Zhang Y; McMahon TJ; Abdulmalik O; Safo MK
    Molecules; 2022 Oct; 27(20):. PubMed ID: 36296435
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New antisickling agents.
    Labie D
    Haematologia (Budap); 1983; 16(1-4):105-8. PubMed ID: 6679483
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Established and experimental treatments for sickle cell disease.
    De Franceschi L; Corrocher R
    Haematologica; 2004 Mar; 89(3):348-56. PubMed ID: 15020275
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical Implications of the Association of Fetal Hemoglobin with Peripheral Oxygen Saturation in Sickle Cell Disease.
    Abdulmalik O; Ataga KI
    EBioMedicine; 2017 Oct; 24():26-27. PubMed ID: 28890145
    [No Abstract]   [Full Text] [Related]  

  • 26. Increased hemoglobin affinity for oxygen with GBT1118 improves hypoxia tolerance in sickle cell mice.
    Dufu K; Williams AT; Muller CR; Walser CM; Lucas A; Eaker AM; Alt C; Cathers BE; Oksenberg D; Cabrales P
    Am J Physiol Heart Circ Physiol; 2021 Aug; 321(2):H400-H411. PubMed ID: 34213392
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nitric oxide reduces sickle hemoglobin polymerization: potential role of nitric oxide-induced charge alteration in depolymerization.
    Ikuta T; Thatte HS; Tang JX; Mukerji I; Knee K; Bridges KR; Wang S; Montero-Huerta P; Joshi RM; Head CA
    Arch Biochem Biophys; 2011 Jun; 510(1):53-61. PubMed ID: 21457702
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel approaches to the treatment of sickle cell disease: the potential of histone deacetylase inhibitors.
    Okam MM; Ebert BL
    Expert Rev Hematol; 2012 Jun; 5(3):303-11. PubMed ID: 22780210
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antisickling effect of chrysin is associated with modulation of oxygenated and deoxygenated haemoglobin via alteration of functional chemistry and metabolic pathways of human sickle erythrocytes.
    Nwankwo HC; Idowu AA; Muhammad A; Waziri AD; Abubakar YS; Bashir M; Erukainure OL
    Hum Exp Toxicol; 2021 Dec; 40(12_suppl):S108-S124. PubMed ID: 34151613
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increasing haemoglobin oxygen affinity to prevent sickling: abnormal haemoglobin variants as models.
    Franklin IM; Huehns ER; Rosemeyer MA
    Br J Haematol; 1986 Oct; 64(2):319-29. PubMed ID: 3778826
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting sickle cell disease root-cause pathophysiology with small molecules.
    Saunthararajah Y
    Haematologica; 2019 Sep; 104(9):1720-1730. PubMed ID: 31399526
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sickle cell paths converge on hydroxyurea.
    Platt OS
    Nat Med; 1995 Apr; 1(4):307-8. PubMed ID: 7585059
    [No Abstract]   [Full Text] [Related]  

  • 33. Etavopivat, a Pyruvate Kinase Activator in Red Blood Cells, for the Treatment of Sickle Cell Disease.
    Schroeder P; Fulzele K; Forsyth S; Ribadeneira MD; Guichard S; Wilker E; Marshall CG; Drake A; Fessler R; Konstantinidis DG; Seu KG; Kalfa TA
    J Pharmacol Exp Ther; 2022 Mar; 380(3):210-219. PubMed ID: 35031585
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting HbS Polymerization.
    Ferrone FA
    Semin Hematol; 2018 Apr; 55(2):53-59. PubMed ID: 30616807
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Allosteric control of hemoglobin S fiber formation by oxygen and its relation to the pathophysiology of sickle cell disease.
    Henry ER; Cellmer T; Dunkelberger EB; Metaferia B; Hofrichter J; Li Q; Ostrowski D; Ghirlando R; Louis JM; Moutereau S; Galactéros F; Thein SL; Bartolucci P; Eaton WA
    Proc Natl Acad Sci U S A; 2020 Jun; 117(26):15018-15027. PubMed ID: 32527859
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting βCys93 in hemoglobin S with an antisickling agent possessing dual allosteric and antioxidant effects.
    Kassa T; Strader MB; Nakagawa A; Zapol WM; Alayash AI
    Metallomics; 2017 Sep; 9(9):1260-1270. PubMed ID: 28770911
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overview of pathophysiology and rationale for treatment of sickle cell anemia.
    Rodgers GP
    Semin Hematol; 1997 Jul; 34(3 Suppl 3):2-7. PubMed ID: 9317195
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hydroxyurea, sickle cell disease and renal transplantation.
    Allen A; Scoble J; Snowden S; Hambley H; Bellingham A
    Nephron; 1997; 75(1):106-7. PubMed ID: 9031282
    [No Abstract]   [Full Text] [Related]  

  • 39. [From Hemoglobin SS to SF: interest of hydroxyurea in the management of sickle cell disease in two Congolese children and review of the literature].
    Nkashama GM; Wakamb GK; Mulangu AM; Nkashama GM; Kupa BK; Numbi OL
    Pan Afr Med J; 2015; 21():124. PubMed ID: 26327961
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rational Drug Design of Peptide-Based Therapies for Sickle Cell Disease.
    Olubiyi OO; Olagunju MO; Strodel B
    Molecules; 2019 Dec; 24(24):. PubMed ID: 31842406
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.